Bayesian approaches for comparative effectiveness research

Clinical Trials

Volumn 9, Issue 1, 2012, Pages 37-47

  Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAYES THEOREM; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; DATA BASE; DEFIBRILLATOR; FOLLOW UP; HAZARD RATIO; HUMAN; MAMMOGRAPHY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

BAYES THEOREM; COMPARATIVE EFFECTIVENESS RESEARCH; DEFIBRILLATORS, IMPLANTABLE; MAMMOGRAPHY;

EID: 84857069889     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511417470     Document Type: Conference Paper

References (30)

1. Agency for Healthcare Research and Quality. What is comparative effectiveness research? Rockville, MD. Available at: http://www. effectivehealthcare.ahrq.gov/index.cfm/what-is-comparative-effectiveness- research1/ (accessed 9 November 2010).
2. Berry DA. A case for Bayesianism in clinical trials (with discussion). Stat Med. 1993 ; 12: 1377-404 (Pubitemid 23258824)
3. Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials. 2005 ; 2: 295-300 (Pubitemid 41306270)
4. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power?. Control Clin Trials. 1986 ; 7: 8-17 (Pubitemid 16166393)
5. Berry SM, Ishak KJ, Luce BR, Berry DA. Bayesian meta-analysis for comparative effectiveness and informing coverage decisions. Med Care. 2010 ; 48: S137-44
6. SandersGDInoueLSamsaG. Use of Bayesian techniques in randomized clinical trials: a CMS case study. Technology Assessment Report, Project ID: STAB0508. Agency for Healthcare Research and Quality, Rockville, MD, (2009). Available at: http://www1.cms.gov/determinationprocess/downloads/id65TA.pdf, Comments available from: http://www.ahrq.gov/clinic/ta/comments/bayesian/ (accessed 9 November 2010).
7. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular dysfunction. Ann Int Med. 2007 ; 147: 251-62 (Pubitemid 351664582)
8. Gordis L, Berry DA, Chu SY, et al. Breast cancer screening for women ages 40-49. J Nat Cancer Inst. 1997 ; 89: 1015-26
9. Berry DA. Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1998 ; 90: 1431-9 (Pubitemid 28482007)
10. Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Int Med. 2009 ; 151: 727-37
11. Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 2006 ; 368: 2053-60 (Pubitemid 44855105)
12. Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006 ; 36: 30-6
13. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998 ; 351: 1451-67
14. Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 ; 97: 1195-203 (Pubitemid 41258225)
15. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Eng J Med. 2005 ; 353: 1784-92 (Pubitemid 41549890)
16. Kalager M, Zelen M, Langmark F, Adami H-O. Effect of screening mammography on breast-cancer mortality in Norway. N Eng J Med. 2010 ; 363: 1203-10
17. The Institute of Medicine. Rewarding Provider Performance: Aligning Incentives in Medicare. The National Academies Press, Washington, DC, (2006). Available at: http://www.nap.edu/catalog.php?record-id=11723#toc (accessed 10 October 2010).
18. Porter ME, Teisberg EO Redefining Health Care: Creating Value-Based Competition on Results. Boston, MA: Harvard Business School Press ; 2006 :
19. Berry DA. Guest Editorial. Comparing survival outcomes across centers-Biases Galore. The Cancer Lett. 2011 ; 37: 7-10
20. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Eng J Med. 1985 ; 312: 1604-08 (Pubitemid 15062653)
21. U.S. Food and Drug Administration. Science and research special topics: critical path initiative. Available at: http://www.fda.gov/ScienceResearch/ SpecialTopics/CriticalPathInitiative/default.htm (accessed 9 November 2010).
22. U.S. Food and Drug Administration. Guidance for industry. Adaptive design clinical trials for drugs and biologics, February (2010). Available at: http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/ Guidances/UCM201790.pdf (accessed 9 November 2010).
23. U.S. Food and Drug Administration. Food and Drug Administration Modernization Act of (1997). Public Law 105-115, 105th Congress. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/ FullTextofFDAMAlaw/default.htm (accessed 9 November 2010).
24. U.S. Food and Drug Administration. Medical Devices. Guidance for the use of Bayesian statistics in medical device clinical trials, February5, 2010. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm071072.htm (accessed 9 November 2010).
25. Centers for Medicare and Medicaid Services. MEDCAC Meetings. Bayesian statistical methods and Medicare evidence. June17, (2009). Available at: https://146.123.140.205/mcd/viewmcac.asp?from2=viewmcac.asp&where= index&mid=49& (accessed 9 November 2010).
26. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006 ; 5: 27-36
27. Berry SM, Carlin B, Lee JJ, Müller P Bayesian Adaptive Methods of Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC Press ; 2010 :
28. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 ; 86: 97-100
29. Foundation for the National Institutes of Health. Investigation of serial studies to predict your therapeutic response with imaging and molecular analysis. Breast cancer I-SPY 2 trial. Available at: http://www.ispy2.org (accessed November 9, 2010).
30. WinslowR. A new Rx for medicine. The Saturday Essay. The Wall Street Journal. 2October22010. Available at: http://online.wsj.com/article/ SB10001424052748703882404575520190576846812.html (accessed 9 November 9 2010).